Home » SciClone Acquires Clinical-Stage Pancreatic Cancer Compound
SciClone Acquires Clinical-Stage Pancreatic Cancer Compound
SciClone Pharmaceuticals, Inc. announced
that it has acquired the exclusive rights in the United States and Canada to develop
and commercialize RP101, a clinical-stage compound for the treatment of cancer.
SciClone acquired the rights from Resistys, Inc., a wholly owned subsidiary of
Avantogen Oncology, Inc.
Genetic
Engineering News
KEYWORDS cancer
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct